Stable deceleration of Walker 256 tumor growth was detected in Brattleboro rats with vasopressin synthesis defect in comparison with normal WAG rats. In contrast to continuous tumor growth typical of rats, the growth of this tumor in Brattleboro rats was negligible and was observed during the first 15-18 days after transplantation, after which the tumor regressed and disappeared. The effect was age-dependent and was more pronounced in old animals. Repeated injection of Walker 256 cells does not lead to tumor development, which attested to direct involvement of the immune system in the detected phenomenon.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10517-006-0362-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Involvement of CXCL12/CXCR4 in CB2 receptor agonist-attenuated morphine tolerance in Walker 256 tumor-bearing rats with cancer pain.
Eur J Med Res
December 2024
Department of Anesthesiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150081, China.
While low-dose cannabinoid 2 (CB2) receptor agonists attenuate morphine tolerance in cancer pain models, chemokine ligand 12 (CXCL12)/chemokine receptor 4 (CXCR4) expression induces morphine tolerance. Whether CB2 receptor agonists attenuate morphine tolerance by modulating CXCL12/CXCR4 signaling or whether CXCL12/CXCR4 signaling affects the mu opioid receptor (MOR) in the development of morphine tolerance in cancer pain remains unclear. In this study, we investigated the attenuation of morphine tolerance by a non-analgesic dose of the CB2 receptor agonist AM1241, focusing specifically on the modulation of CXCL12/CXCR4 signaling and its effect on the MOR.
View Article and Find Full Text PDFStudy on the therapeutic effect and some immune factors by methotrexate modified superparamagnetic nanoparticles in rat mammary tumors.
Nanoscale Adv
November 2024
Department of Thoracic Oncology, The Affiliated Hospital of Guizhou Medical University and the Affiliated of Cancer Hospital of Guizhou Medical University Guiyang 550004 China
: this study investigates the efficacy, immunological impact, and preliminary safety of methotrexate (MTX) modified magnetic FeO nanoparticles in thermochemotherapy for mammary tumors in rats. : transmission electron microscopy images revealed that the MTX-modified magnetic FeO nanoparticles are nearly spherical, approximately 10 nm in diameter. Chemically co-precipitated PEI-modified magnetic nanoparticles were utilized for thermotherapy, while MTX-modified nanoparticles were employed for thermochemotherapy.
View Article and Find Full Text PDFLiu-Shen-Wan inhibits PI3K/Akt and TRPV1 signaling alleviating bone cancer pain in rats.
Cancer Biol Ther
December 2024
Department of Integrated Traditional Chinese and Western Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Patients with advanced-stage cancers often suffer from severe pain caused by bone metastasis and destruction, for which effective treatment options are limited. Liu-Shen-Wan (LSW) is a widely recognized herbal formula utilized for pain relief. This study aims to elucidate the effects of LSW on bone cancer pain (BCP).
View Article and Find Full Text PDFDextran-Graft-Polyacrylamide/Zinc Oxide Nanoparticles Inhibit of Cancer Cells in vitro and in vivo.
Int J Nanomedicine
November 2024
Faculty of Chemistry, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Introduction: Tumor drug resistance and systemic toxicity are major challenges of modern anticancer therapy. Nanotechnology makes it possible to create new materials with the required properties for anticancer therapy.
Methods: In this research, Dextran-graft-Polyacrylamide/ZnO nanoparticles were used.
Targeted therapy: P2X3 receptor silencing in bone cancer pain relief.
J Biochem Mol Toxicol
November 2024
Department of Anesthesiology, The Third Center of PLA General Hospital, Beijing, China.
Bone cancer pain remains a significant clinical challenge, often refractory to conventional treatments. The upregulation of the P2X3 receptor in the dorsal root ganglia has been implicated in the pathogenesis of bone cancer pain. This study aimed to elucidate the role of the P2X3 receptor in this context and assess the therapeutic potential of receptor silencing.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!